Ann: Trading Halt, page-70

The other question is given Neuren’s drug was recently approved my main question is given Neuren has been granted ODD for the Rett syndrome does this give them 7 year marketing exclusivity or not? The FDA approval for Daybue didn’t mention exclusivity granted for their drug (they got paediatric rare drug PRV) so I am guessing we can also stand to get marketing approval if we fly past phase 3.

https://data-api.marketindex.com.au/api/v1/announcements/XASX:NEU:2A1436933/pdf/inline/fda-approves-daybue-the-first-treatment-for-rett-syndrome